ArticleDrug delivery and translational research2012
Aptamer-conjugated polymeric nanoparticles for targeted cancer therapy.
Article in Drug delivery and translational research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nucleolin-Targeting AS1411 Aptamer-Conjugated Nanospheres for Targeted Treatment of Glioblastoma.Pharmaceutics · 2024Article
- Aptamer and its applications in neurodegenerative diseases.Cellular and molecular life sciences : CMLS · 2017Review
- Fitness Landscapes of Functional RNAs.Life (Basel, Switzerland) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in cancer nanotechnology have led to the emergence of aptamer-enabled technologies to diagnose and treat cancer. Aptamers with their high binding sensitivity and specificity are highly attractive for a wide variety of applications in molecular targeting. Aptamer-escorted drug-loaded polymeric nanoparticles represent a promising technology, which facilitates controlled release and targeted approach to deliver drugs to the desired site with marginal or any collateral damage. By properly integrating these nanobased approaches with the established cancer research findings could help to resolve some of the existing problems in the current conventional cancer therapy. In this review, we discuss the progresses achieved in the aptamer mediated nanoparticle drug delivery and properties of nanoparticles, which play a significant role in developing the aptamer-nanoparticle bioconjugates. In addition, we highlight the recent preclinical works involving these bioconjugates as cancer therapeutics.
Identifiers
25787323What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.